Tamoxifen in cancer therapy

Neoplasma

Volumn 47, Issue 1, 2000, Pages 3-7

  Novotny L ^a   Rauko, P ^b   Vachalkova A ^b   Peterson Biggs, M ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c MINISTRY OF HEALTH   (Kuwait)

Author keywords

Cancer; Gynecology; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BROMOCRIPTINE; CHOLESTEROL; CISPLATIN; DACARBAZINE; DIGNOTAMOXI; DNA; ESTROGEN RECEPTOR; FOLLITROPIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISTUBOL; LUTEINIZING HORMONE; MAMOFEN; MESSENGER RNA; NOLTAM; NORTAMOXIFEN; NOVOFEN; PROTEIN BCL 2; RIBOSOME RNA; TAMIFEN; TAMOXEN; TAMOXIFEN; TAMOXIFEN CITRATE; TESTOSTERONE; UNCLASSIFIED DRUG; WARFARIN;

BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DNA ADDUCT; DRUG ABSORPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; ENDOMETRIUM CANCER; HOT FLUSH; HUMAN; INFERTILITY; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NAUSEA; NONHUMAN; SHORT SURVEY; VOMITING;

EID: 0034065325     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. ANDERSON, C.: Breast cancer. How not to publicize a misconduct finding. Science, 263, 1994, 1679.
2. CALTAGIRONE, S., RANELLETI, F.O., RINELLI, A., MAGGIANO, N., COLASANTE, A., MUSIANI, P., AIELLO, F.G.: Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am. J. Respir. Cell. Mol. Biol., 17, 1997, 51-59.
3. CHENG, A.L., CHUANG, S.E., FINE, R.L., YEH, K.H., LIAO, C.M., LAY, J.D., CHEN, D.S.: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem. Pharmacol., 55, 1998, 523-531.
4. CI PDQ Clinical Trial Search. Bethesda, USA, National Cancer Institute 1999.
5. FERLINI, C., SCAMBIA, G., MARONE, M., DISTEFANO, M., GAGGINI, C., FERRANDINA, G., FATTOROSSI, A., ISOLA, G., BENEDETTI PANICI, P., MANCUSO, S.: Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br. J. Cancer, 79, 1999, 257-263.
6. FISHER, B., CONSTANTINO, J.P., REDMOND, C.K., FISHER, E.R., WICKERHAM, D.L., CRONIN, W.M.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst., 86, 1994, 527-537.
7. FISHER, B., COSTANTINO, J., REDMOND, C., POISSON, R., BOWMAN, D., COUTURE, J., DIMITROV, N.V., WOLMARK, N., WICKERHAM, D.L. FISHER, E.R. et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with nodenegative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med., 320, 1989, 479-484.
8. FORD, L.G., BRAWLEY, O.W., PERLMAN, J.A., NAYFIELD, S.G., JOHNSON, K.A., KRAMER, B.S.: The potential for hormonal prevention trials. Cancer, 74, 1994, 2726-2733.
9. GELMAN, E.P.: Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin. Oncol., Suppl. 1, 24, 1997, S165-S170.
10. HASHIMOTO, M., INOUE, S., MURAMATSU, M., MASLIAH, E.: Estrogens stimulate tamoxifen-induced neuronal cell apoptosis in vitro: a possible nongenomic action. Biochem. Biophys. Res. Commun., 240, 1997, 464-470.
11. HORIMI, T., TAKASAKI, M., TOKI, A., NISHIMURA, W., MORITA, S.: The beneficial effect of tamoxifen therapy in patients with resected adenocarcinoma of the pancreas. Hepatogastroenterology, 43, 1996, 1225-1229.
12. KADIOGLU, T.C., KOKSAL, I.T., TUNC, M., NANE, I., TELLALOGLU, S.: Treatment of idiopathic and postvaricoselectomy oligozoospermia with oral tamoxifen citrate. B.J.U. Int., 83, 1999, 646-648.
13. KARDINAL, C.G., VEITH, R.: Prevention of breast cancer in high-risk women. J. State Med. Soc., 151, 1999, 198-201.
14. KEDAR, R.P., BOURNE, T.H., POWLES, T.J., COLLINS, W.P. ASHLEy, S.E., COSGROVE, D.O., CAMPBELL, S.: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet, 1994, 1318-1324.
15. MARSHALL, E.: Tamoxifen: Hanging in the balance. Science, 264, 1994, 1524.
16. SEIFERT, M., GALID, A., KUBISTA, E.: Estrogen replacement therapy in women with a history of breast cancer. Maturitas, 32, 1999, 63-68.
17. NEVEN, P., VERGOTE, I.: Controversies regarding tamoxifen and uterine carcinoma. Curr. Opin. Obstet. Gynecol., 10, 1998, 9-14.
18. NOLA, M., JUKIC, S., ILIC-FORKO, J., BASIC, D., UZAREVIC, B., PETROVECKI, M., SUCHANEK, E., SKRABLIN, S., DOTLIC, S., MARUSIC, M.: Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Gynecol. Oncol., 72, 1999, 331-336.
19. RIESTRA, S., RODRIGUEZ, M., DELGADO, M., SUAREZ, A., GONZALEZ, N., DE LA MATA, M., DIAZ, G., MINO-FUGAROLAS, G., RODRIGO, L.: Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J. Clin. Gastroenterol, 26, 1998, 200-203.
20. ROSENBERG, S.A., YANG, J.C., SCHWARTZENTRUBER, D.J., HWU, P., MARINCOLA, F.M., TOPALIAN, S.L., SEIPP, C.A., EINHORN, J.H., WHITE, D.E., STEINBERG, S.M.: Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J. Clin. Oncol., 17, 1999, 968-975.
21. SAUNDERS, M.P. SALISBURY, A.J., O'BYRNE, K.J., SOULIOTIS, V.L., VARCOE, S.M., TALBOT, D.C., KYRTOPOULOS, S.A., HARRIS, A.L.: A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dac-arbazine. Anticancer Res., 17(6D), 1997, 4677-4680.
22. Scottish Cancer Trials Office (MRC): Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet, 1987, 171-175.
23. SIKIC, B.I.: Antineoplastic agents. In: Modern Pharmacology, 2nd ed. Eds: Graig, C.R., Stitzel, R.E. Boston/Toronto, Little, Brown and Co. 1986, 823-824.
24. STROBL, J.S., THOMAS, J.A.: Estrogens, progestins, and antiestrogens. In: Modern Pharmacology, 2nd ed. Eds: Graig, C.R., Stitzel, R.E. Boston/Toronto, Little, Brown and Co. 1986, 889-891.
25. Tamoxifen Citrate. In: Mosby's Complete Drug Reference. Physicians GenRx. Ed. BeDell, L.S. St. Louis, Mosby 1997, 1948-1950.
26. Tamoxifen Citrate. In: American Hospital Formulary Service Drug Information® 98, American Society of Health-System Pharmacists. Bethesda 1998, 934-938.
27. TERASHIMA, I., SUZUKI, N., SHIBUTANI, S.: Mutagenic potential of alpha-(N2-deoxyguanosine) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res., 59, 1999, 2091-2095.